The Opportunity Aspect Ratio 1200 384


It’s time to transform outcomes for cancer patients with a new potential AML treatment

Current treatment of Acute Myeloid Leukemia (AML) generally consists of chemotherapy followed by a Hematopoietic Cell Transplant (HCT) to attempt to clean out the bone marrow of remaining cancer cells.

This clinical approach as an AML treatment has not significantly changed in decades, however outcomes remain poor with around 40% of transplanted patients experiencing cancer relapse, and these patients having two-year survival rates of less than 20%. One reason is that newly transplanted patients are unable to receive targeted cancer therapies since such therapies would be toxic to the fragile HCT. A more effective approach to HCTs is long overdue.

The Concept

Vor Bio is developing a novel AML treatment approach—Edit HSCs to enable treatment with powerful targeted therapies post-transplant.